IRISIN AND INTERLEUKINS-33 AND -37 LEVELS IN PATIENTS WITH ISCHEMIC HEART DISEASE UNDER OBESITY INFLUENCE
IRISIN AND INTERLEUKINS-33 AND -37 AND ISCHEMIC HEART DISEASE
Keywords:
ischemic heart disease, angina pectoris, obesity, interleukin, irisin
Abstract
Objective. The aim of this work was to investigate the obesity influence on irisin and interleukins 33 and 37 levels in patients with coronary heart disease.
Methods. The first group was pr esented by 36 patients with coronary artery disease (CAD) and obesity. The comparison group consisted of 33 patients with coronary artery disease with normal body weight. The control group included 30 practically healthy persons. The irisin and interleukins levels were measured by ELISA. Obesity was indicated as increased body mass index (BMI) ≥ 30 kg/m2.
Results. The study showed that irisin was reduced 127.36 (107.52 – 137.88) ng / ml) in group with stable angina pectoris compared with the controls 147.92 (139.04 - 172.55) ng / ml, p = 0.290. Patients with combined coronary artery disease and obesity had significantly increased IL-33 levels (123.56 ± 32.38 pg / ml, p = 0.004) and IL-37 (131.74 ± 24.17 pg / ml, p = 0.004). Multivariate regression analyses showed that BMI positively correlated with the serum irisin in CAD obese patients (β = 0.255, p = 0.039).
Conclusions. The coexistence of obesity in patients with stable angina is suggested to be significant factor of irisin diminishing and interleukins 33 and 37 levels increasing. Body mass index had direct correlation with the irisin concentrations in the obese patients with coronary artery disease.
References
1. Csige I, Ujvárosy D, Szabó Z, et al. The Impact of Obesity on the Cardiovascular System. J Diabetes Res 2018; 3407306.
2. Mohammed SE, Ismail P, Huzwah K, Asmah R, Yehia A. Obesity and inflammation:the linking mechanism and the complications. Arch Med Sci 2017; 13(4):851–63.
3. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and Inflammation:Epidemiology, Risk Factors, and Markers of Inflammation. Int J Endocrinol 2013; Article ID 678159.
4. Schwartz C, O’Grady K, Lavelle EC, Fallon PG. Interleukin 33:an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur J Immunol 2016; 46:1091–1100.
5. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37:a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22(3):127–47.
6. Briganti SI, Gaspa G, Tabacco G, et al. Irisin as a regulator of bone and glucose metabolism. Minerva Endocrinol 2018; 43(4):489-500.
7. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020; 41(3):407–77.
8. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 2017; 13(6):324-37.
9. Sahin-Efe A, Upadhyay J, Ko BJ, et al. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes:a cross sectional and a prospective case-control study nested in the Normative Aging Study. Metabolism 2018; 79:24–32.
10. Yin C, Hu W, Wang M, Lv W, Jia T, Xiao Y. Irisin as a mediator between obesity and vascular inflammation in Chinese children and adolescents. Nutr Metab Cardiovasc Dis 2020; 30(2):320–29.
11. Löffler D, Müller U, Scheuermann K, et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab 2015; 100(4):1289–99.
12. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 2013; 39:125–30.
13. Crujeiras AB, Pardo M, Arturo RR, et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol 2014; 26(2):198–207.
14. Bonfante ILP, Chacon-Mikahil MPT, Brunelli DT, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk. Arch Endocrinol Metab 2017; 61(6):524–33.
15. Shim YS, Kang MJ, Yang S, Hwang IT. Irisin is a biomarker for metabolic syndrome in prepubertal children. Endocr J 2018; 65(1):23–31.
16. Liu BW, Yin FZ, Qi XM, Fan DM, Zhang Y. The levels of serum irisin as a predictor of insulin resistance in han chinese adults with metabolically healthy obesity. Clin Lab 2017; 63(5):881–86.
17. Jia J, Yu F, Wei WP, et al. Relationship between circulating irisin levels and overweight/obesity:A meta-analysis. World J Clin Cases 2019; 7(12):1444-55.
18. Fukushima Y, Kurose S, Shinno H, et al. Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects. Diabetes Metab J 2016; 40(5):386-95.
19. Elizondo-Montemayor L, Gonzalez-Gil AM, Tamez-Rivera O, et al. Association between Irisin, hs-CRP, and Metabolic Status in Children and Adolescents with Type 2 Diabetes Mellitus. Mediators Inflamm 2019; 2019:6737318.
20. Eslampour E, Ebrahimzadeh F, Abbasnezhad A, Khosroshahi MZ, Choghakhori R, Asbaghi O. Association between Circulating Irisin and C-Reactive Protein Levels:A Systematic Review and Meta-Analysis. Endocrinol Metab (Seoul) 2019; 34(2):140-49.
22. Altara R, Giordano M, Norden ES, et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol 2017; 8:160.
22. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. Polic B. The “Big Bang” in obese fat:events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45:2446–56.
23. Helmersson-Karlqvist J, Björklund-Bodegård K, Larsson А, Basu S. 24-Hour ambulatory blood pressure associates inversely with prostaglandin F (2α), interleukin-6 and F(2)-isoprostane formation in a Swedish population of older men. Int. J. Clin. Exp. Med 2012; 5(2):145-53.
24. Thomas D. and Apovian C. Macrophage functions in lean and obese adipose tissue. Metabolism 2017; 72:120-43.
25. Pirola L. and Ferraz JC. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem 2017; 8(2):120-28.
26. Liu R. and Nikolajczyk BS. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. Front Immunol 2019; 10:1587.
27. Hasan A, Al-Ghimlas F, Warsame S, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol 2014; 15:19.
28. Zeyda M, Wernly B, Demyanets S, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 2013; 37:658–65.
29. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31:2080–89.
30. Chai M, Zhang HT, Zhou YJ, et al. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. J Geriatr Cardiol 2017; 14(5):285–91.
31. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine 2018; 59(2):260-74.
32. Korta P, Pocheć E, Mazur-Biały A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. Medicina (Kaunas) 2019; 55(8):485.
2. Mohammed SE, Ismail P, Huzwah K, Asmah R, Yehia A. Obesity and inflammation:the linking mechanism and the complications. Arch Med Sci 2017; 13(4):851–63.
3. Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and Inflammation:Epidemiology, Risk Factors, and Markers of Inflammation. Int J Endocrinol 2013; Article ID 678159.
4. Schwartz C, O’Grady K, Lavelle EC, Fallon PG. Interleukin 33:an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur J Immunol 2016; 46:1091–1100.
5. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37:a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22(3):127–47.
6. Briganti SI, Gaspa G, Tabacco G, et al. Irisin as a regulator of bone and glucose metabolism. Minerva Endocrinol 2018; 43(4):489-500.
7. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes:The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020; 41(3):407–77.
8. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 2017; 13(6):324-37.
9. Sahin-Efe A, Upadhyay J, Ko BJ, et al. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes:a cross sectional and a prospective case-control study nested in the Normative Aging Study. Metabolism 2018; 79:24–32.
10. Yin C, Hu W, Wang M, Lv W, Jia T, Xiao Y. Irisin as a mediator between obesity and vascular inflammation in Chinese children and adolescents. Nutr Metab Cardiovasc Dis 2020; 30(2):320–29.
11. Löffler D, Müller U, Scheuermann K, et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab 2015; 100(4):1289–99.
12. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 2013; 39:125–30.
13. Crujeiras AB, Pardo M, Arturo RR, et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol 2014; 26(2):198–207.
14. Bonfante ILP, Chacon-Mikahil MPT, Brunelli DT, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk. Arch Endocrinol Metab 2017; 61(6):524–33.
15. Shim YS, Kang MJ, Yang S, Hwang IT. Irisin is a biomarker for metabolic syndrome in prepubertal children. Endocr J 2018; 65(1):23–31.
16. Liu BW, Yin FZ, Qi XM, Fan DM, Zhang Y. The levels of serum irisin as a predictor of insulin resistance in han chinese adults with metabolically healthy obesity. Clin Lab 2017; 63(5):881–86.
17. Jia J, Yu F, Wei WP, et al. Relationship between circulating irisin levels and overweight/obesity:A meta-analysis. World J Clin Cases 2019; 7(12):1444-55.
18. Fukushima Y, Kurose S, Shinno H, et al. Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects. Diabetes Metab J 2016; 40(5):386-95.
19. Elizondo-Montemayor L, Gonzalez-Gil AM, Tamez-Rivera O, et al. Association between Irisin, hs-CRP, and Metabolic Status in Children and Adolescents with Type 2 Diabetes Mellitus. Mediators Inflamm 2019; 2019:6737318.
20. Eslampour E, Ebrahimzadeh F, Abbasnezhad A, Khosroshahi MZ, Choghakhori R, Asbaghi O. Association between Circulating Irisin and C-Reactive Protein Levels:A Systematic Review and Meta-Analysis. Endocrinol Metab (Seoul) 2019; 34(2):140-49.
22. Altara R, Giordano M, Norden ES, et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol 2017; 8:160.
22. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. Polic B. The “Big Bang” in obese fat:events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45:2446–56.
23. Helmersson-Karlqvist J, Björklund-Bodegård K, Larsson А, Basu S. 24-Hour ambulatory blood pressure associates inversely with prostaglandin F (2α), interleukin-6 and F(2)-isoprostane formation in a Swedish population of older men. Int. J. Clin. Exp. Med 2012; 5(2):145-53.
24. Thomas D. and Apovian C. Macrophage functions in lean and obese adipose tissue. Metabolism 2017; 72:120-43.
25. Pirola L. and Ferraz JC. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem 2017; 8(2):120-28.
26. Liu R. and Nikolajczyk BS. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. Front Immunol 2019; 10:1587.
27. Hasan A, Al-Ghimlas F, Warsame S, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol 2014; 15:19.
28. Zeyda M, Wernly B, Demyanets S, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 2013; 37:658–65.
29. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31:2080–89.
30. Chai M, Zhang HT, Zhou YJ, et al. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. J Geriatr Cardiol 2017; 14(5):285–91.
31. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine 2018; 59(2):260-74.
32. Korta P, Pocheć E, Mazur-Biały A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. Medicina (Kaunas) 2019; 55(8):485.
Published
2022/03/07
Section
Original Scientific Paper